What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

Original reporting
Published Nov 6, 2026, 1:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 1:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What Omada Health (OMDA) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$OMDABearishMed
01

Why it matters

The guidance downgrade reflects seasonal enrollment patterns and slower employer decision‑making on GLP‑1 coverage, which may weigh on the stock until the holiday slowdown passes.

02

Market read

Omada's Q3 earnings call provides fresh guidance that could influence investor sentiment in the health‑tech sector.

03

What to watch

Cash position of $243 M and debt‑free balance sheet may allow strategic acquisitions or price promotions that could offset the seasonal dip.

Relevance 7/10Novelty 7/10Timing: today

Background

Omada Health is a Nasdaq‑listed digital health company focusing on chronic‑condition management and employer‑sponsored wellness programs.

Company-level read

Ticker impact

$OMDABearishHigh confidence
Context

Omada Health guided Q4 revenue below Q3 levels and noted a sequential decline in members, providing new guidance after its Q3 earnings call.

Expected impact

likely downward pressure as the market prices in weaker Q4 revenue outlook

Evidence & confidence

The company explicitly lowered its revenue expectations and warned of lower enrollment, which typically triggers a sell‑off in the short term.

Market effects

Signals potential softness in digital health and employer‑sponsored wellness programs during holiday seasons.

U.S. employer‑benefits market may see slower adoption of GLP‑1 related programs.

Limited to U.S. health‑tech investors; no immediate global macro effect.

Counterpoint

If Omada's GLP‑1 partnership gains traction later in the year, the guidance could be overly conservative, offering a buying opportunity.

Key entities

  • Sean Duffy

    Co‑founder and CEO, will transition to executive chair on Jan 1 2027.

  • Shao

    Executive discussing enrollment trends and partnership updates.

Related articles

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.

$OMDAMed

Omada Health Reports Third Quarter 2026 Results

Omada Health, Inc. (OMDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Omada Health Reports Third Quarter 2026 Results • Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million • Revenue Grew 34% and Total Members Increased 36% Year over Year • Raises Full Year 2026 Financial Outlook SAN FRANCISCO - November 5, 2026 - Omada H

$OMDALowAI 8/10

Omada Health reports weight loss study results for GLP-1 program

Omada Health (NASDAQ:OMDA) presented a 12-week study at the World Obesity and Weight Management Congress, showing its GLP-1 Care Track program led to 6.0% average weight loss vs. 3.3% for usual care. The study, published in Diabetes, Obesity and Metabolism, involved 245 adults with obesity. Omada's program also improved body composition, well-being, and reduced depression/anxiety symptoms.